Abiopharma

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

(10% Negative) CYCLERION THERAPEUTICS, INC. (CYCN) Announces Delay in agents Development Timeline Due to Patient Enrollment Issues, Regulatory Process

(99% Neutral) AINOS, INC. (AIMD) Provides Business Update

Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry

(75% Positive) Atossa Therapeutics, Inc. (ATOS) Provides Update on application for metastatic ER+/HER2- Breast Cancer

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

(99% Neutral) GALECTO, INC. (GLTO) Announces New Board Appointment

Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer